Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Inflammatory Myopathies

New classification criteria developed for research

The International Myositis Assessment and Clinical Studies (IMACS) network was established in the late 1990s to develop assessment tools for myositis disease activity. In the course of that work, the need became apparent for reliable classification criteria that were data driven, useful for clinical trial enrolment and research purposes, and were inclusive of adult and paediatric patients. Now, the IMACS-led International Myositis Classification Criteria Project (IMCCP) presents new guidelines that are supported by the ACR and EULAR.

Credit: Macmillan Publishers Limited

The IMCCP comprised experts from several specialties who treat myositis, including rheumatology, dermatology, neurology and paediatrics. Together, these experts designed the study and validation experiments, revised the list of criteria for assessment and designated the inclusion criteria for cases (a diagnosis of known confidence for at least 6 months before inclusion) and comparators (individuals without myositis). In totaly, 976 patients were enrolled from 47 centres in Europe, the United States and Asia, of which 74% were adult and 26% were children; 624 comparators were also included. In looking at different classification techniques, a probability-score model was deemed to have superior discriminating performance compared with sum-of-items and classification-tree approaches and was taken forward and refined.

“The probability-score model gave the best sensitivity and specificity to distinguish myositis based on 16 variables, each given a specific weighted score,” explains corresponding author Ingrid Lundberg. The variables include age of onset, type and location of muscle weakness, skin manifestations, laboratory findings and muscle biopsy findings. “A sum of the score gives a probability of having myositis, where the cut-off score of 55% indicates 'probable' myositis,” Lundberg continues. For those individuals who reach a score of ≥90%, the classification is deemed 'definite'; patients in the probability score range of 50–55% are classed as having 'possible' myositis.

“the most useful feature of the classification system is its in-built flexibility”

Arguably, the most useful feature of the classification system is its in-built flexibility: not all variables need to be assessed to reach a classification of myositis. As the criteria encompass patients with all the major subtypes of myositis — dermatomyositis, polymyositis and inclusion body myositis in adults, and juvenile dermatomyositis in children — those with, for example, heliotrope or Gottron rashes can be classified as having dermatomyositis without undergoing muscle biopsy. Additionally, the research network developed a simple classification tree to help researchers determine the subtype of myositis.

Going forward, the classification score will need to be validated in independent cohorts of patients and comparators. “We will also have to update the criteria when we have access to cohorts who have been tested for emerging myositis-specific autoantibodies,” explains Lundberg, as the current classification only includes anti-Jo1 autoantibodies.

References

  1. 1

    Lundberg, I. E. et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.40320 (2017)

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Razzak, M. New classification criteria developed for research. Nat Rev Rheumatol 13, 694 (2017). https://doi.org/10.1038/nrrheum.2017.192

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing